However, in contrast to its widespread expressed in normal tissues, downregulation of SPARCL1 has been reported as a putative tumor-suppressor factor in a wide variety of human malignancies including breast, colorectal, prostate and pancreatic cancers [13–19]. This evidence concerns the gene SPARCL1 and familial pancreatic carcinoma.